Research on biomarkers in ovarian cancer patients
Official title: Biomarker Discovery Project in High Grade Serous Ovarian Cancer
Run by University Health Network, Toronto · NCT03419689 · Data updated 2026-11-12
This study is collecting blood and tissue samples from women with advanced ovarian cancer to see if certain markers can help doctors understand the disease better and make more informed treatment choices.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 510 (estimated) |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 7 sites (Barrie, Ontario and 6 other locations) |
| Status | Recruiting |
| Started | January 8, 2018 |
| Main results expected | June 8, 2028 |
| Study ends | June 8, 2028 |
| Registry record updated | December 4, 2025 |
| Trial ID | NCT03419689 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with a histological diagnosis of stage III or IV high grade serous ovarian, tubal, or primary peritoneal cancer.
✕Probably not a fit
Patients with early-stage (I and II) high grade serous cancers or those with other tumor histologies will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study collects biological samples, including blood, tumor tissue, and other fluids, from patients diagnosed with advanced gynecological cancers, specifically high grade serous ovarian, tubal, or primary peritoneal cancer. The samples will be analyzed for biomarkers that may help in understanding the disease and guiding treatment decisions. Participants will receive the results of the testing, which can be shared with their treating physicians to inform their care. The study aims to enhance the understanding of ovarian cancer and improve patient outcomes through biomarker research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for patients with advanced ovarian cancer.
How similar studies have gone: While this approach to biomarker research is common, the specific focus on advanced gynecological cancers may provide novel insights that have not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histological diagnosis of stage III or IV high grade serous ovarian, tubal or primary peritoneal cancer. * Must be 18 years of age or older. * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. * Have a life expectancy greater than or equal to 6 months. * Able to provide adequate informed consent. * Willing to undergo blood or fluid collection and tumour biopsy * Patients enrolled at the time of surgery must agree to have part of their tumour used for the purpose of the study. * Archival tissue must be available for patients that are enrolled at the time of progression. Exclusion Criteria: * Must not have early stage (I and II) high grade serous, tubal or primary peritoneal cancer. * Must not have other tumour histology other than high grade serous. * Must not have contraindication to tumour biopsy and/or blood sampling.
Where it's running
-
Royal Victoria Regional Health Centre
Barrie, Ontario, Canada Recruiting -
Kingston Health Sciences Centre
Kingston, Ontario, Canada Recruiting -
London Health Sciences Centre
London, Ontario, Canada Recruiting -
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada Recruiting -
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada Recruiting -
Princess Margaret Cancer Centre
Toronto, Ontario, Canada Recruiting
Show 1 more location
-
Juravinski Cancer Centre
Hamilton, Ontario, Canada Active not recruiting
Study contacts
- Principal investigator: Amit Oza, M.D. — Princess Margaret Cancer Centre
- Study coordinator: Amit Oza, M.D.
- Email: amit.oza@uhn.ca
- Phone: 416-946-2818
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
NMTCuff vs standard TOF monitoring during gynecologic oncology surgery
This study tests whether NMTCuff monitoring can better detect neuromuscular recovery than standard TOF monitoring in women undergoing laparoscopic gynecologic cancer surgery.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
Personalized supervised exercise program for adults with breast or gynecologic cancer
A small pilot study will test a supervised, personalized exercise program to see if it is safe, feasible, and acceptable for adults with a history of breast or gynecologic cancer.
-
Cesium-131 brachytherapy to preserve organs in recurrent cervical or endometrial cancer
This study tests whether implanting small cesium-131 seeds can provide targeted radiation to vaginal recurrences of cervical or endometrial cancer in patients who previously had pelvic radiation, with the goal of preserving organs.
-
National registry of endometrial cancer cases in Italy
This project will collect clinical and molecular information from adults treated for endometrial cancer at participating Italian oncology centers to see if a national database can improve understanding of outcomes and care.
-
High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)
This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.